Immunovia AB (IMMNOV) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to the Immunovia Q2 Interim Report 2026 Conference Call. I am Lorenzo, the Chorus Call Operator. I would like to remind you that all participants will be in listen-only mode and the conference is being recorded. The presentation will be followed by a Q&A session. You can register for questions at any time by pressing star and 1 on your telephone. For operator assistance, please press star and 0. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Jeff Porcellin, CEO. Please go ahead, sir. Thank you very much, and thank you to all of you for joining us today for the review of Immunovia's second quarter of 2026. As we will share, we have achieved important milestones in the commercialization of pancreas share, and we are transitioning to the second phase of the Pancreasure test launch. We're also excited about the progress that we continue to make in the pursuit of Medicare coverage, and we'll share updates on our efforts there. I'm also pleased with our business development progress, as we have ongoing conversations with potential partners. As you can imagine, I won't be able to share a lot about the specifics of those opportunities but wanted you to know that we are focused on business development and are pursuing a number of paths there. So, for today's call, we will focus initially on the commercial uptake and traction of the pancreas share test. We'll also talk a little bit about some of the drivers of growth in the second half of the year. My colleague, Adam, will cover our Q2 financial results and our cash position. And then I will come back to discuss clinical studies that are in progress and our reimbursement efforts, as well as those business development opportunities t...